Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on markers of VTE and CVD risk, in PCOS. In a double-blind, placebo-controlled, randomized trial, 72 overweight and/or insulin-resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference in change (baseline to follow-up) in plasminogen activator inhibitor-1 levels and in thrombin generation test parameters: endogenous thrombin potential, peak thrombin concentration, lag time and time to peak. Mean weight loss was 5.2 kg (95% CI 3.0–7.5 kg, P < 0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group, peak thrombin concentration decreased by 16.71 nmol/L (95% CI 2.32–31.11, P < 0.05) and lag time and time to peak increased by 0.13 min (95% CI 0.01–0.25, P < 0.05) and 0.38 min (95% CI 0.09–0.68, P < 0.05), respectively, but there were no between-group differences. There was a trend toward 12% (95% CI 0–23, P = 0.05) decreased plasminogen activator inhibitor-1 in the liraglutide group, and there was a trend toward 16% (95% CI −4 to 32, P = 0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend toward improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point toward beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies compared the liraglutide 1.8 mg/day vs. placebo for 26 weeks and demonstrated a greater efficacy in terms of reduction of body weight and waist circumference (WC) in the liraglutide group [54–56].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Thrombin generation and fibrin clot structure
Wolberg, A. S. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.11.001 · Cited by 747
Cited by
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
“The LIPT-study was a double-blind, placebo-controlled RCT.8 In short, inclusion criteria were PCOS (Rotterdam criteria), BMI > 25 kg/m2 and/or presence of IR.”
MethodSelf-citationPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
“136 137 A meta-analysis of eight randomised controlled trials concluded that GLP-1 agonists were more effective than metformin in improving homeostasis model assessment-insulin resistance (standard mean difference −0.40, 95% confidence interval −0.74 to −0.06), abdominal circumference (−0.45, −0.89…”
InfluentialWang, F. ‐., Wu, Y., Zhu, Y. ‐., Ding, T., Batterham, R. L., Qu, F., & Hardiman, P. J. (2018) · Obesity Reviews · doi:10.1111/obr.12720 · Cited by 92
“0 mg d 1 for 12 weeks were applied (40,41), 1.”
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Zhao, X., Huang, K., Zheng, M., & Duan, J. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0332-5 · Cited by 49
Jensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50
“In addition, there was an improvement in fibrinolytic activity [50].”
BackgroundEffect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections · doi:10.1530/ec-17-0327 · Cited by 38
Self-citationPharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Ma, R., Ding, X., Wang, Y., Deng, Y., & Sun, A. (2021) · Medicine · doi:10.1097/md.0000000000026295 · Cited by 34
Lin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-99622-4 · Cited by 35
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
Mokou, M., Yang, S., Zhan, B., Geng, S., Li, K., Yang, M., Yang, G., Deng, W., Liu, H., Liu, D., et al. (2020) · Mediators of Inflammation · doi:10.1155/2020/2483435 · Cited by 30
“In addition, GLP-1RA has been used to treat women with PCOS in a few small sample studies, demonstrating weight loss and improved IR, but none investigated the impact on IR-related cytokines [29, 30, 32].”
BackgroundUnravelling Polycystic Ovary Syndrome and Its Comorbidities
Kim, K.-W. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21043 · Cited by 44
“The rates of positive thyroid autoantibodies were reported to be higher in women with PCOS than in controls,74 and subclinical hypothyroidism was present in 10%–25% of women with PCOS.75 The presence of overt thyroid disease was 3.6-times higher in PCOS patients than in controls, and prescriptions for thyroid medicine…”
BackgroundInfluentialGlintborg, D., Mumm, H., Holst, J. J., & Andersen, M. (2017) · Endocrine Connections · doi:10.1530/ec-17-0034 · Cited by 26
“In support of this hypothesis, total testosterone levels were unchanged during treatment with GLP-1 despite significant weight loss in patients with PCOS (28, 29).”
BackgroundGlintborg, D., & Andersen, M. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000410 · Cited by 28
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update
Profili, N. I., Castelli, R., Gidaro, A., Manetti, R., Maioli, M., Petrillo, M., Capobianco, G., & Delitala, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030698 · Cited by 29
“Future studies should elucidate the risk of CVD in women with PCOS, specifically in the postmenopausal years, so that women can be counseled accurately.”
BackgroundMedical Treatment and Comorbidity in Polycystic Ovary Syndrome: An Updated Review
Glintborg, D., & Andersen, M. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.014 · Cited by 20
Forslund, M., Wändell, P. E., Forsberg, L., Österberg, M., Dagerhamn, J., Wernersson, E., Fredriksson, M. K., Ringborg, A., & Hirschberg, A. L. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag033 · Cited by 39
Sridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01730-8 · Cited by 24
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Kumbhar, P., Chavan, R., Darekar, S., Kolekar, K. A., Sequeira, A., Vishwas, S., Gupta, G., Paudel, K. R., Singh, S. K., Dua, K., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03578-7 · Cited by 16
Janež, A., Herman, R., Poredoš, P., Mikhailidis, D. P., Blinc, A., Šabović, M., Studen, K. B., Jezovnik, M. K., Schernthaner, G.-H., Anagnostis, P. G., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611269146230920073301 · Cited by 11
Harrath, A. H., Jalouli, M., Al-Zharani, M. M., & Rahaman (2026) · Biomolecules · doi:10.3390/biom16050626 · Cited by 9
“[84,85] Footnotes: AMPK (adenosine monophosphate-activated protein kinase), SHBG (sex hormone-binding globulin), MI (myo-inositol), DCI (D-chiro-inositol), GLP-1R (glucagon-like peptide-1 receptor).”
Machado, M. F., Shunk, T., Hansen, G., Harvey, C., Fulford, B., Hauf, S., Schuh, O., Kaldas, M., Arcaroli, E., Ortiz, J. P., et al. (2024) · Cureus · doi:10.7759/cureus.66691 · Cited by 19
“Reductions in testosterone levels and an increase in SHBG following GLP-1 therapy indicate potential advantages for restoring hormonal equilibrium among PCOS patients [31-35].”
BackgroundResultInfluentialThe Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome
Chatzis, P., Τζιόμαλος, Κ., Pratilas, G. C., Makris, V., Sotiriadis, A., & Dinas, K. D. (2018) · Folia Medica · doi:10.2478/folmed-2018-0036 · Cited by 8
Lacey, H., Attersley-Smith, S., Kathryn, Whyte, M., Shawe, J., & Stone, S. (2023) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.05011-9 · Cited by 11
Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis
Cheng, P.-L., & Chang, H. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113333 · Cited by 8
Cannarella, R., Calogero, A. E., Barbagallo, F., Petralia, C. M. B., Aversa, A., Condorelli, R. A., & Vignera, S. L. (2025) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2025.200331 · Cited by 4
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
“These findings support a potential reduction in baseline thrombogenicity with liraglutide in PCOS and warrant larger, adequately powered studies to confirm effects on venous thromboembolism (VTE) and cardiovascular disease (CVD) risk pathways [22].”
InfluentialZaky, D. A., Sayed, R. H., & Mohamed, Y. S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110212 · Cited by 5
Song, E., Fang, Y., Li, X., Fu, W., He, H., Gao, Z., Tian, X., & Gao, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1809416 · Cited by 3
Shaharyar, A., Chaudhry, S., Jha, V., Bhadada, S. K., & Walia, R. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.02.008 · Cited by 2
“48,49 In women with obesity with PCOS unresponsive to lifestyle changes, semaglutide achieved weight loss in ~80%, restored menstrual regularity (weight-loss independent), and improved basal insulin, FBG, and HOMA.”
Jan, A., Ullah, A., Ali, S. S., Akbar, R., & Waheed, B. (2025) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.040.02.10
Novel Therapeutic Intervention for PCOS-1
Bajaj, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010010
Parekh, R. S., Inban, P., Thai, A., Agrawal, A., Kudaiarov, D., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102150
Banerjee, I., Krissheeven, M., Pandey, N., Banerjee, S., Robinson, J., & Banerjee, I. (2026) · Cureus · doi:10.7759/cureus.115758 · Cited by 2
Pilcová, R. (2026) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2026/007
Georgy, S. M., Elnaidany, N. F., Abdelmoneum, N. A., Salem, S. A. M., Salem, H. F., & Sarhan, R. M. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10995-z
“Clinically, the higher post-treatment pregnancy propor - tion in the Liraglutide group remains highly relevant [ 18] It is important to note that timing of metformin initiation may influence miscarriage outcomes; Cheshire et al. indicated that continuing metformin throughout the first trimester was…”
Metadata
- Authors
- Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nylander, Malin
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2017-02
- Volume
- 6
- Issue
- 2
- Pages
- 89-99
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC5424770
- OpenAlex
- W2580304737
- Cited by
- 44
- References
- 48
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 3
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gentofte Hospital
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- polycystic ovary syndrome, liraglutide, venous thromboembolism, cardiovascular risk, thrombogenic potential, thrombin generation, plasminogen activator inhibitor-1, fibrinolysis, weight loss, insulin resistance, overweight women, GLP-1 receptor agonists, endogenous thrombin potential, time delay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.